UK – NICE backs Roche’s Gazyvaro, Pfizer’s Lorviqua in new guidance

The two new cancer drugs will treat follicular lymphoma and lung cancer

Cost-effectiveness watchdog NICE has recommended routine NHS funding in England for two new cancer drugs – Roche’s Gazyvaro for follicular lymphoma (FL) and Pfizer’s lung cancer therapy Lorviqua.

Gazyvaro (obinutuzumab) has been cleared as part of a treatment regimen with bendamustine – followed by Gazyvaro alone as a maintenance therapy – for FL patients who have relapsed after first-line treatment with rituximab, with alone or with other drugs.

Roche’s drug has been recommended by NICE for routine NHS alongside chemotherapy as a first-line treatment for advanced FL since 2018, having been rejected earlier on the grounds it was too expensive.

At the time, NICE said second-line, maintenance use of the drug should be covered by the Cancer Drugs Fund (CDF) rather than the NHS’ regular budget as the evidence for the drug’s benefits in this setting wasn’t sufficiently strong…